ENHANCING
THE
NATURE
Immunofusion is a biotechnology company founded in 2020. Our company is focused on the development of next generation CAR-T cell products as well as solving unmet medical needs in the area of cell based therapies. Another direction is the development of next generation immunocytokines for the treatment of solid tumours.
A novel tandem CAR-T for MCL and CLL
The 5th generation tandem chimeric antigen receptor (TanCAR) for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
TanCAR recognizes two functionally cross talking targets expressed on CLL and MCL. The signaling domain of TanCAR includes a novel cytokine domain that ensures the resistance of СAR-modified T-cells to functional exhaustion and maintains their persistence.
Currently, FDA approved CAR T-therapies for B-cell lymphomas have a number of limitations: on-target off-tumor toxicity, antigen escape, CAR T-cell dysfunction due to exhaustion, and senescence. Dual antigen targeting prevents B-cell aplasia and antigen loss. The inclusion of a cytokine domain in CAR T gives a signal 3 for T-cell upon antigen stimulation and thus provides resistance to exhaustion and improves persistence.
Immunocytokines composition
The new treatment platform is comprised of 4 different immunocytokines, each fulfiIling its own but complementary function for efficient anti-tumor immune-response engagement in TME.
The main function is to accomplish homing and full activation of T-cell and NK-cells in the TME, after that fostering different chains of the immune system directly in the immunosuppressive TME.
Such a therapeutic approach could be an independent treatment modality to release all pathways of endogenous anticancer immunity as well as an additive therapy to any cellular therapy (CAR-T cells, NK cells) or cancer vaccine to enhance anticancer efficacy.
NEWS
15/02/2023
Immunofusion is attending #BIOEuropeSpring! Join us in Basel March 20-22, 2023 and let’s meet!
10/10/2022
Thanks to Simone Haubner and Robert Möbius for sightseeing tour in Leipzig Biopark. Great place with lots of opportunities.
06/10/2022
Great week on Bio 2022.BIO-Europe is the place to meet the world under one roof and discover the latest innovations which will advance the medicines of tomorrow. Thanks to all the participants for opportunities and new friends.
20/05/2022
TransCure bioServices starting a new one pilot study in CD34+ humanized mice engrafted with tumor cells in our Immunocytokine compositions project.
09/05/2022
An emerging COVID‑19 pandemic resulted in a global crisis, but also accelerated vaccines development and antibodies discovery. By screening of the more than 1011 diversity synthetic humanized VHH antibody library against different SARS-CoV-2 variants of concern (VoC) receptor binding domain (RBD) we have identified a number of nanomolar-range affinity binders. In order to explore the most robust and fast method for affinity improvement we performed affinity maturation by CDR1 and CDR2 shuffling and avidity engineering by multivalent trimeric VHH fusion protein construction. As a result, H7-Fc and G12x3-Fc binders were developed with the affinities in nM and pM range respectively. Importantly, their affinities are weakly influenced by SARS-CoV2 VoC mutations. The plaque reduction neutralization test (PRNT) resulted in IC50 = 100 ng\ml and 9.6 ng\ml for H7-Fc and G12x3-Fc antibodies respectively for emerging Omicron variant. Therefore, these VHH could be expand the present landscape of SARS-CoV-2 neutralization binders with the therapeutic potential for present and future SARS-CoV-2 variants.
